Steroid-refractory chronic graft-versus-host disease: treatment options and patient management

Daniel Wolff; Giancarlo Fatobene; Vanderson Rocha; Nicolaus Kröger; Mary E Flowers

doi:10.1038/s41409-021-01389-5

Steroid-refractory chronic graft-versus-host disease: treatment options and patient management

Standard

Steroid-refractory chronic graft-versus-host disease: treatment options and patient management. / Wolff, Daniel; Fatobene, Giancarlo; Rocha, Vanderson; Kröger, Nicolaus; Flowers, Mary E.

in: BONE MARROW TRANSPL, Jahrgang 56, Nr. 9, 09.2021, S. 2079-2087.

Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Review › Forschung

Harvard

Wolff, D, Fatobene, G, Rocha, V, Kröger, N & Flowers, ME 2021, 'Steroid-refractory chronic graft-versus-host disease: treatment options and patient management', BONE MARROW TRANSPL, Jg. 56, Nr. 9, S. 2079-2087. https://doi.org/10.1038/s41409-021-01389-5

APA

Wolff, D., Fatobene, G., Rocha, V., Kröger, N., & Flowers, M. E. (2021). Steroid-refractory chronic graft-versus-host disease: treatment options and patient management. BONE MARROW TRANSPL, 56(9), 2079-2087. https://doi.org/10.1038/s41409-021-01389-5

Vancouver

Wolff D, Fatobene G, Rocha V, Kröger N, Flowers ME. Steroid-refractory chronic graft-versus-host disease: treatment options and patient management. BONE MARROW TRANSPL. 2021 Sep;56(9):2079-2087. https://doi.org/10.1038/s41409-021-01389-5

Bibtex

@article{abad6737be26458e98653d73a1fcae4f,

title = "Steroid-refractory chronic graft-versus-host disease: treatment options and patient management",

abstract = "Chronic graft-versus-host disease (cGVHD) is one of the major causes of late mortality after allogenic hematopoietic stem cell transplantation. Moderate-to-severe cGVHD is associated with poor health-related quality of life and substantial disease burden. While corticosteroids with or without calcineurin inhibitors comprise the first-line treatment option, the prognosis for patients with steroid-refractory cGVHD (SR-cGVHD) remains poor. The mechanisms underlying steroid resistance are unclear, and there are no standard second-line treatment guidelines for patients with SR-cGVHD. In this review, we provide an overview on current treatment options of cGVHD and use a series of theoretical case studies to elucidate the rationale of choices of second- and third-line treatment options for patients with SR-cGVHD based on individual patient profiles.",

author = "Daniel Wolff and Giancarlo Fatobene and Vanderson Rocha and Nicolaus Kr{\"o}ger and Flowers, {Mary E}",

note = "{\textcopyright} 2021. The Author(s).",

year = "2021",

month = sep,

doi = "10.1038/s41409-021-01389-5",

language = "English",

volume = "56",

pages = "2079--2087",

journal = "BONE MARROW TRANSPL",

issn = "0268-3369",

publisher = "NATURE PUBLISHING GROUP",

number = "9",

}

RIS

TY - JOUR

T1 - Steroid-refractory chronic graft-versus-host disease: treatment options and patient management

AU - Wolff, Daniel

AU - Fatobene, Giancarlo

AU - Rocha, Vanderson

AU - Kröger, Nicolaus

AU - Flowers, Mary E

PY - 2021/9

Y1 - 2021/9

N2 - Chronic graft-versus-host disease (cGVHD) is one of the major causes of late mortality after allogenic hematopoietic stem cell transplantation. Moderate-to-severe cGVHD is associated with poor health-related quality of life and substantial disease burden. While corticosteroids with or without calcineurin inhibitors comprise the first-line treatment option, the prognosis for patients with steroid-refractory cGVHD (SR-cGVHD) remains poor. The mechanisms underlying steroid resistance are unclear, and there are no standard second-line treatment guidelines for patients with SR-cGVHD. In this review, we provide an overview on current treatment options of cGVHD and use a series of theoretical case studies to elucidate the rationale of choices of second- and third-line treatment options for patients with SR-cGVHD based on individual patient profiles.

AB - Chronic graft-versus-host disease (cGVHD) is one of the major causes of late mortality after allogenic hematopoietic stem cell transplantation. Moderate-to-severe cGVHD is associated with poor health-related quality of life and substantial disease burden. While corticosteroids with or without calcineurin inhibitors comprise the first-line treatment option, the prognosis for patients with steroid-refractory cGVHD (SR-cGVHD) remains poor. The mechanisms underlying steroid resistance are unclear, and there are no standard second-line treatment guidelines for patients with SR-cGVHD. In this review, we provide an overview on current treatment options of cGVHD and use a series of theoretical case studies to elucidate the rationale of choices of second- and third-line treatment options for patients with SR-cGVHD based on individual patient profiles.

U2 - 10.1038/s41409-021-01389-5

DO - 10.1038/s41409-021-01389-5

M3 - SCORING: Review article

C2 - 34218265

VL - 56

SP - 2079

EP - 2087

JO - BONE MARROW TRANSPL

JF - BONE MARROW TRANSPL

SN - 0268-3369

IS - 9

ER -